Clinical trial
A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered…
NCT00287118 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00287118 |
|---|---|
| Title | A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis |
| Official title | A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Candidates for Systemic Therapy for Psoriasis, Psoriasis |
| Intervention type | Drug |
| Interventions | Efalizumab |
| Enrollment | 189 |
| Start date | Oct 27, 2004 |
| Primary completion | May 30, 2006 |
| Completion | May 30, 2006 |
| First posted | Feb 6, 2006 |
| Last update posted | Apr 3, 2018 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: